Stay updated on DCVax-L for Newly Diagnosed GBM Clinical Trial
Sign up to get notified when there's something new on the DCVax-L for Newly Diagnosed GBM Clinical Trial page.

Latest updates to the DCVax-L for Newly Diagnosed GBM Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe ClinicalTrials.gov record for the DCVax-L glioblastoma trial is displayed, with study design, eligibility requirements, participating locations, investigators, and outcome measures. It replaces the prior access-denied page.SummaryDifference84%

- Check15 days agoChange DetectedThe site footer’s revision identifier changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check22 days agoChange DetectedA site-wide announcement says NIH is transitioning to the term “Super Intelligence” in place of “Artificial Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check29 days agoChange DetectedThe ClinicalTrials.gov page continues to display a 403 Forbidden error; its footer revision changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check36 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check57 days agoChange DetectedThe study page now displays a 403 Forbidden error, with the content replaced by a standard header/footer indicating restricted access. The previous detailed study information and navigation sections have been removed from view.SummaryDifference17%

Stay in the know with updates to DCVax-L for Newly Diagnosed GBM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the DCVax-L for Newly Diagnosed GBM Clinical Trial page.